These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
200 related articles for article (PubMed ID: 19525451)
1. Improved selection of patients for hepatic surgery of colorectal liver metastases with (18)F-FDG PET: a randomized study. Ruers TJ; Wiering B; van der Sijp JR; Roumen RM; de Jong KP; Comans EF; Pruim J; Dekker HM; Krabbe PF; Oyen WJ J Nucl Med; 2009 Jul; 50(7):1036-41. PubMed ID: 19525451 [TBL] [Abstract][Full Text] [Related]
2. The role of FDG-PET in the selection of patients with colorectal liver metastases. Wiering B; Krabbe PF; Dekker HM; Oyen WJ; Ruers TJ Ann Surg Oncol; 2007 Feb; 14(2):771-9. PubMed ID: 17086488 [TBL] [Abstract][Full Text] [Related]
3. 18F-FDG PET scanning correlates with tissue markers of poor prognosis and predicts mortality for patients after liver resection for colorectal metastases. Riedl CC; Akhurst T; Larson S; Stanziale SF; Tuorto S; Bhargava A; Hricak H; Klimstra D; Fong Y J Nucl Med; 2007 May; 48(5):771-5. PubMed ID: 17475966 [TBL] [Abstract][Full Text] [Related]
4. The impact of fluor-18-deoxyglucose-positron emission tomography in the management of colorectal liver metastases. Wiering B; Krabbe PF; Jager GJ; Oyen WJ; Ruers TJ Cancer; 2005 Dec; 104(12):2658-70. PubMed ID: 16315241 [TBL] [Abstract][Full Text] [Related]
5. Role of FDG-PET staging in selecting the optimum patient for hepatic resection of metastatic colorectal cancer. Strasberg SM; Dehdashti F J Surg Oncol; 2010 Dec; 102(8):955-9. PubMed ID: 21165998 [TBL] [Abstract][Full Text] [Related]
6. Added value of positron emission tomography imaging in the surgical treatment of colorectal liver metastases. Wiering B; Adang EM; van der Sijp JR; Roumen RM; de Jong KP; Comans EF; Pruim J; Dekker HM; Ruers TJ; Krabbe PF; Oyen WJ Nucl Med Commun; 2010 Nov; 31(11):938-44. PubMed ID: 20856152 [TBL] [Abstract][Full Text] [Related]
7. Improved long-term survival after resection of colorectal liver metastases following staging with FDG positron emission tomography. Abbadi RA; Sadat U; Jah A; Praseedom RK; Jamieson NV; Cheow HK; Whitley S; Ford HE; Wilson CB; Harper SJ; Huguet EL J Surg Oncol; 2014 Sep; 110(3):313-9. PubMed ID: 24737685 [TBL] [Abstract][Full Text] [Related]
8. Comparison of multiphase CT, FDG-PET and intra-operative ultrasound in patients with colorectal liver metastases selected for surgery. Wiering B; Ruers TJ; Krabbe PF; Dekker HM; Oyen WJ Ann Surg Oncol; 2007 Feb; 14(2):818-26. PubMed ID: 17136470 [TBL] [Abstract][Full Text] [Related]
9. F18-FDG-PET evaluation of patients for resection of colorectal liver metastases. Huguet EL; Old S; Praseedom RK; Balan KK; Gibbs P; Jamieson NV Hepatogastroenterology; 2007 Sep; 54(78):1667-71. PubMed ID: 18019690 [TBL] [Abstract][Full Text] [Related]
10. Value of positron emission tomography with [F-18]fluorodeoxyglucose in patients with colorectal liver metastases: a prospective study. Ruers TJ; Langenhoff BS; Neeleman N; Jager GJ; Strijk S; Wobbes T; Corstens FH; Oyen WJ J Clin Oncol; 2002 Jan; 20(2):388-95. PubMed ID: 11786565 [TBL] [Abstract][Full Text] [Related]
11. Controversies in the management of colorectal liver metastases: role of PET and PET/CT. Wiering B; Vogel WV; Ruers TJ; Oyen WJ Dig Surg; 2008; 25(6):413-20. PubMed ID: 19212113 [TBL] [Abstract][Full Text] [Related]
12. Utility of 18F-FDG PET and contrast-enhanced CT scan in the assessment of residual liver metastasis from colorectal cancer following adjuvant chemotherapy. Carnaghi C; Tronconi MC; Rimassa L; Tondulli L; Zuradelli M; Rodari M; Doci R; Luttmann F; Torzilli G; Rubello D; Al-Nahhas A; Santoro A; Chiti A Nucl Med Rev Cent East Eur; 2007; 10(1):12-5. PubMed ID: 17694495 [TBL] [Abstract][Full Text] [Related]
13. Five-year survival after resection of hepatic metastases from colorectal cancer in patients screened by positron emission tomography with F-18 fluorodeoxyglucose (FDG-PET). Fernandez FG; Drebin JA; Linehan DC; Dehdashti F; Siegel BA; Strasberg SM Ann Surg; 2004 Sep; 240(3):438-47; discussion 447-50. PubMed ID: 15319715 [TBL] [Abstract][Full Text] [Related]
14. Trends in nontherapeutic laparotomy rates in patients undergoing surgical therapy for hepatic colorectal metastases. Pawlik TM; Assumpcao L; Vossen JA; Buijs M; Gleisner AL; Schulick RD; Choti MA Ann Surg Oncol; 2009 Feb; 16(2):371-8. PubMed ID: 19020939 [TBL] [Abstract][Full Text] [Related]
15. Survival of patients evaluated by FDG-PET before hepatic resection for metastatic colorectal carcinoma: a prospective database study. Strasberg SM; Dehdashti F; Siegel BA; Drebin JA; Linehan D Ann Surg; 2001 Mar; 233(3):293-9. PubMed ID: 11224615 [TBL] [Abstract][Full Text] [Related]
16. A meta-analysis exploring the role of PET and PET-CT in the management of potentially resectable colorectal cancer liver metastases. Daza JF; Solis NM; Parpia S; Gallinger S; Moulton CA; Belley-Cote EP; Levine MN; Serrano PE Eur J Surg Oncol; 2019 Aug; 45(8):1341-1348. PubMed ID: 30928334 [TBL] [Abstract][Full Text] [Related]
17. Preoperative FDG-PET-scan in patients with resectable colorectal liver metastases does not improve overall survival: a retrospective analyses stratified by clinical risk score. Ayez N; de Ridder J; Wiering B; Oyen WJ; de Wilt JH; Verhoef C Dig Surg; 2013; 30(4-6):451-8. PubMed ID: 24458160 [TBL] [Abstract][Full Text] [Related]
18. Clinical impact of FDG PET-CT in patients with potentially operable metastatic colorectal cancer. Briggs RH; Chowdhury FU; Lodge JP; Scarsbrook AF Clin Radiol; 2011 Dec; 66(12):1167-74. PubMed ID: 21867996 [TBL] [Abstract][Full Text] [Related]
19. Role of FDG-PET in surgical management of patients with colorectal liver metastases. Teague BD; Morrison CP; Court FG; Chin VT; Costello SP; Kirkwood ID; Maddern GJ ANZ J Surg; 2004 Aug; 74(8):646-52. PubMed ID: 15315564 [TBL] [Abstract][Full Text] [Related]
20. The economic impact of 18FDG positron emission tomography in the surgical management of colorectal cancer with hepatic metastases. Zubeldia JM; Bednarczyk EM; Baker JG; Nabi HA Cancer Biother Radiopharm; 2005 Aug; 20(4):450-6. PubMed ID: 16114993 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]